The prevalence of metabolic associated fatty liver disease in US adults increased significantly from 28.4% in 1999-2002 to 35.8% in 2011-2016, accompanied by high cardiovascular and renal burdens.
Cross-Sectional (n=19,617)
The prevalence of MAFLD in the US has significantly increased over time, carrying a substantial and growing burden of cardiovascular and renal comorbidities.
Absolute Event Rate: 35.8% vs 28.4%
p-value: p=<0.001
BACKGROUND: Non-communicable chronic diseases have become the leading causes of disease burden worldwide. The trends and burden of "metabolic associated fatty liver disease" (MAFLD) are unknown. We aimed to investigate the cardiovascular and renal burdens in adults with MAFLD and non-alcoholic fatty liver disease (NAFLD). METHODS: Nationally representative data were analyzed including data from 19,617 non-pregnant adults aged ≥20 years from the cross-sectional US National Health and Nutrition Examination Survey periods, 1999 to 2002, 2003 to 2006, 2007 to 2010, and 2011 to 2016. MAFLD was defined by the presence of hepatic steatosis plus general overweight/obesity, type 2 diabetes mellitus, or evidence of metabolic dysregulation. RESULTS: The prevalence of MAFLD increased from 28.4% (95% confidence interval 26.3-30.6) in 1999 to 2002 to 35.8% (33.8-37.9) in 2011 to 2016. In 2011 to 2016, among adults with MAFLD, 49.0% (45.8-52.2) had hypertension, 57.8% (55.2-60.4) had dyslipidemia, 26.4% (23.9-28.9) had diabetes mellitus, 88.7% (87.0-80.1) had central obesity, and 18.5% (16.3-20.8) were current smokers. The 10-year cardiovascular risk ranged from 10.5% to 13.1%; 19.7% (17.6-21.9) had chronic kidney diseases (CKDs). Through the four periods, adults with MAFLD showed an increase in obesity; increase in treatment to lower blood pressure (BP), lipids, and hemoglobin A1c; and increase in goal achievements for BP and lipids but not in goal achievement for glycemic control in diabetes mellitus. Patients showed a decreasing 10-year cardiovascular risk over time but no change in the prevalence of CKDs, myocardial infarction, or stroke. Generally, although participants with NAFLD and those with MAFLD had a comparable prevalence of cardiovascular disease and CKD, the prevalence of MAFLD was significantly higher than that of NAFLD. CONCLUSIONS: From 1999 to 2016, cardiovascular and renal risks and diseases have become highly prevalent in adults with MAFLD. The absolute cardiorenal burden may be greater for MAFLD than for NAFLD. These data call for early identification and risk stratification of MAFLD and close collaboration between endocrinologists and hepatologists.
Zhang et al. (Fri,) conducted a cross-sectional in Metabolic associated fatty liver disease (MAFLD) (n=19,617). Time period (2011-2016) vs. Time period (1999-2002) was evaluated on Prevalence of MAFLD (95% CI 33.8-37.9, p=<0.001). The prevalence of metabolic associated fatty liver disease in US adults increased significantly from 28.4% in 1999-2002 to 35.8% in 2011-2016, accompanied by high cardiovascular and renal burdens.